secwatch.observer — SEC 8-K summary
======================================

Issuer:     TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
CIK:        0000818686
Form:       8-K
Filed at:   2023-09-28T23:59:59+00:00
Accession:  0001193125-23-245614
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Teva appoints Christine Fox as EVP U.S. Commercial; Sven Dethlefs departing Nov 17
--------------------------------------------------------------------------------

- Sven Dethlefs, EVP North America Commercial, to leave Teva on November 17, 2023 after 15 years.
- Christine Fox appointed EVP U.S. Commercial; previously Global President, Gene Therapies at Novartis.
- Fox brings 30+ years industry experience from Novartis, Amgen, Merck, Takeda.
- CEO Richard Francis thanked Dethlefs and expressed confidence in Fox's ability to lead U.S. business.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/818686/000119312523245614/0001193125-23-245614-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/818686/000119312523245614/d469125d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-245614

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer